Evaluating glutamatergic transmission in schizophrenia.
Our findings with schizophrenia and the glutamate system have relied on the characterization of the clinical response of patients to ketamine and their functional brain imaging response (rCBF) to the drug. Prior to the human studies reported here, we had evaluated the region activation characteristics and pharmacology of PCP and its congener MK 801 in animals. What I will report in this paper has been individually reported elsewhere but brought together here in a new synthesis.
Tamminga
Carol A
CA
University of Texas Southwestern Medical School, Dallas, Texas, 75390, USA. ctamming@mprc.umaryland.edu
Lahti
Adrienne C
AC
Medoff
Deborah R
DR
Gao
Xue-Min
XM
Holcomb
Henry H
HH
D000818:Animals; D016291:Dizocilpine Maleate / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005971:Glutamates / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007649:Ketamine / Q000494:pharmacology; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*
D018691:Excitatory Amino Acid Antagonists; D005971:Glutamates; D007649:Ketamine; D016291:Dizocilpine Maleate